Fortis Therapeutics Closes $40 Million Series A Financing to Advance Novel Anti-CD46 Therapeutic to Treat Late-Stage Prostate Cancer and Multiple Myeloma

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2PhSynt
via IFTTT